tdkventures-logo
TDK Worldwide
Portfolio
>
Mekonos

Mekonos: Coupling digital microfluidics with nanoengineered MEMS onto a single integrated chip for cell/gene therapies

Gene and cell therapy will never be the same with Mekonos’ groundbreaking delivery technology. Using frontier research in microfluidics and MEMS engineering, they have built a single chip system that can deliver variable size, cell precision, payloads achieving unmatched cell delivery yield and viability. This could forever change the development of therapies, and with previously unachievable scalability could mean genetic based cures to those who need them faster than ever hoped.

Mekonos_Anil

"Mekonos and TDK Ventures share synergistic values in our commitment to contribute and enrich society in building a better world. They are also known leaders in the MEMS industry with valuable experience in manufacturing. We look forward to this monumental opportunity to collaborate moving forward, and to work together to bring about new hope and therapies for families everywhere struggling with illness and limited treatment options."

CEO and co-founder, Anil Narasimha

Investment
Announcement

Visit Mekonos

Coverage

11/12/2021: TDK Backs Scalable Cell Engineering with Mekonos

Team members involved with Mekonos

Geetha Dholakia

Portfolio Program Manager

Marc Bouchet

Investment Associate

Anil Achyuta

Managing Director

Other Healthtech Companies

Exo is revolutionizing ultrasound. Their advanced silicon-based chip design works as thousands of tiny nanoscale chips act in symphony together.
Genetesis innovating the diagnostic cardiac space with a new scanning method that is working to save 8 million patients per year that come in for cardiac concerns.
Mojo Lens’ revolutionary design uses a tiny microLED display the size of a grain of sand that empowers you to be your best self through enhancing tech.